ClinicalTrials.gg
RecruitingNCT04251052Updated Nov 6, 2026

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

An interventional study of Bilateral Salpingectomy and Bilateral Salpingectomy with Oophorectomy in Ovarian Carcinoma, sponsored by NRG Oncology. Recruiting at 630 sites in 3 countries. Open to female participants aged 35 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by NRG Oncology · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Sep 2020; still recruiting 6 years 2 months later.
Updated Nov 6, 2026Site recruiting status changed57 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,956
Allocation
Non-randomized
Ages
35 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,780 studies in Ovarian Neoplasms with a site in United States — 275 open to participants now, 452 under way, 46 of them phase 3. Ovarian Neoplasms · United States.

Planned enrollment
19th of 1,499
1,956 · median 47
Started
2020
with 77 others
No phase
202 of 1,780
45 open now
Primary completion
2047-06
later than 447 of 450 live
Registered
1,250th of 1,780
by date

Among the 1,780 studies in Ovarian Neoplasms with a site in United States, this one is the 19th largest by planned enrollment of the 1,499 interventional ones that give a count, is one of 78 that started in 2020, is one of 202 with no phase, reaches primary completion later than 447 of the 450 other live ones, and was the 1,250th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

275 of the 1,780 studies in Ovarian Neoplasms with a site in United States are open now. Recruiting first, the newest first:

270 more — sign in →

All 275 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 35 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,780 studies in Ovarian Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk reduction for women with BRCA1 mutations.

Read the detailed description

PRIMARY OBJECTIVE:

I. To compare the non-inferiority of bilateral salpingectomy (BLS) with delayed oophorectomy to bilateral salpingo-oophorectomy (BSO) to reduce the risk of ovarian cancer among individuals with deleterious BRCA1 germline mutations.

SECONDARY OBJECTIVES:

I. To prospectively assess estrogen deprivation symptoms in pre-menopausal BLS patients as measured by the Functional Assessment of Cancer Therapy - Endocrine Symptom (FACT-ES) subscale compared to pre-menopausal patients in the BSO arm.

II. To determine if health-related quality of life (QOL) (FACT) is negatively impacted by menopausal symptoms (menopausal symptom checklist-Menopausal Symptom Checklist [MSCL]) and sexual dysfunction (Female Sexual Function Index [FSFI]) in pre-menopausal patients who have undergone BLS, in comparison to normative data (MSCL/FACT-ES) and data from pre-menopausal BSO patients.

III. To determine if health-related QOL (FACT) is negatively impacted by cancer distress (Impact of Event Scale [IES]) in individuals who have undergone BLS, in comparison to BSO patients.

IV. To assess medical decision making, as measured by the Shared Decision Making Questionnaire (SDM-Q-9) and Decision Regret Scale (DRS), and determine factors associated with the risk of reducing surgical treatment choice.

V. To assess adverse events, graded using Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0.

EXPLORATORY OBJECTIVES:

I. Sexual dysfunction, as measured by selected Patient-Reported Outcomes Measurement Information System (PROMIS) screener and external sexual function items (pre-menopausal patients).

II. To estimate the cost-effectiveness of BLS compared to BSO for ovarian cancer risk reduction.

III. To assess medical decision making, as measured by the Risk-Reducing Medical Decision Making (RR-MDM) survey, a targeted set of questions on risk reducing surgical treatment choice.

TRANSLATIONAL RESEARCH OBJECTIVE:

I. To bank tissue and blood biospecimens for future research.

OUTLINE: Patients choose between 1 of 2 groups.

GROUP I: Patients undergo bilateral salpingectomy. Patients may then undergo oophorectomy after initial surgery.

GROUP II: Patients undergo bilateral salpingo-oophorectomy.

Patients in both groups also undergo a pelvic or transvaginal ultrasound or pelvic magnetic resonance imaging (MRI) during screening and blood sample collection throughout the trial.

After completion of study, patients are followed up at 10-60 days, 6, 12, and 24 months, and then annually for up to 20 years.

03

Conditions studied

  • Ovarian Carcinoma

Browse trials for

04

Who can participate

Ages eligible
35 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals 35-50 years of age, inclusive
  • Patients who will undergo risk-reducing salpingo-oophorectomy (RRSO) (for the BSO arm) and patients who have declined or elected to defer BSO after proper counselling to clearly explain the standard of care for BRCA1 mutation carriers and are undergoing salpingectomy (for the BLS arm with delayed oophorectomy arm). Concurrently planned hysterectomy with either arm is permitted
  • At least one intact ovary and fallopian tube is in situ at the time of counseling, consent, and registration. Prior hysterectomy is allowed provided it did not include bilateral salpingectomy. Prior tubal ligation is allowed if one ovary and fallopian tube (with fimbria not removed) are present
  • Positive Clinical Laboratory Improvement Act (CLIA)-approved test results for pathogenic or likely pathogenic germline BRCA1 mutation in the patient. Documentation of the result is required
  • Patients may be premenopausal or menopausal
  • Pelvic ultrasound (transvaginal imaging preferred, but transabdominal imaging is acceptable) or pelvic MRI and CA-125 within 180 days of registration
  • The patient or a legally authorized representative must provide study-specific prior to study entry
  • Individuals who are currently pregnant or plan to become pregnant in the future through assisted reproductive technologies and who have received proper counseling are eligible. Individuals who are currently pregnant and plan bilateral salpingectomy at the time of a planned cesarean section are eligible. Patients must understand that they will not be able to become pregnant naturally in the future

Exclusion criteria

Exclusion Criteria:

  • Individuals with a history of any prior cancer who have received cytotoxic chemotherapy within the past 30 days or radiotherapy to abdomen or pelvis at any prior time. Endocrine therapy or maintenance /HER2 targeted therapy is allowed. Maintenance therapy is allowed. Maintenance therapy with PARP in inhibitor is allowed.
  • Prior history of ovarian cancer, including low malignant potential neoplasms (LMP), primary peritoneal carcinoma, or fallopian tube carcinoma
  • Patients medically unfit for the planned surgical procedure
  • Patients with abnormal screening tests (pelvic ultrasound, pelvic MRI, CA-125) suspicious for occult or gross pelvic within the past 180 days

    • An abnormal pelvic ultrasound (or pelvic MRI) is defined as morphologic or structural variations suspicious for ovarian malignancy. Complex cystic lesions felt to represent a benign lesion are not exclusionary. Simple cysts of any size are not exclusionary
    • An abnormal CA-125 is defined as a level > 50U/ml in premenopausal individuals if they are not current users of oral ; an abnormal CA-125 is defined as a level > 40U/ml for premenopausal individuals who are current users of oral contraceptives (Skates 2011). An abnormal CA-125 is defined as a level > 35 U/ml in individuals
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,956 participants (estimated)

Study arms

  • Experimental
    Group I (bilateral salpingectomy)

    Patients undergo bilateral salpingectomy. Patients may then undergo oophorectomy after initial surgery. Patients also undergo a pelvic or transvaginal ultrasound or pelvic MRI during screening and blood sample collection throughout the trial.

    Procedure: Bilateral Salpingectomy · Procedure: Biospecimen Collection · Procedure: Magnetic Resonance Imaging · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Procedure: Transvaginal Ultrasound · Procedure: Ultrasound Imaging

  • Active comparator
    Group II (bilateral salpingo-oophorectomy)

    Patients undergo bilateral salpingo-oophorectomy. Patients also undergo a pelvic or transvaginal ultrasound or pelvic MRI during screening and blood sample collection throughout the trial.

    Procedure: Bilateral Salpingectomy with Oophorectomy · Procedure: Biospecimen Collection · Procedure: Magnetic Resonance Imaging · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Procedure: Transvaginal Ultrasound · Procedure: Ultrasound Imaging

Interventions

  • ProcedureBilateral Salpingectomy

    Undergo bilateral salpingectomy

  • ProcedureBilateral Salpingectomy with Oophorectomy

    Undergo bilateral salpingo-oophorectomy

    Also known as: bilateral salpingo-oophorectomy

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • ProcedureMagnetic Resonance Imaging

    Undergo pelvic MRI

    Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI

  • OtherQuality-of-Life Assessment

    Ancillary studies

    Also known as: Quality of Life Assessment

  • OtherQuestionnaire Administration

    Ancillary studies

  • ProcedureTransvaginal Ultrasound

    Undergo transvaginal ultrasound

    Also known as: transvaginal sonography, TVS, TVU

  • ProcedureUltrasound Imaging

    Undergo pelvic ultrasound

    Also known as: 2-Dimensional Grayscale Ultrasound Imaging, 2-Dimensional Ultrasound Imaging, 2D-US, Ultrasonography, Ultrasound, Ultrasound Test, Ultrasound, Medical, US

06

What researchers measure

Primary outcomes

  1. Time to development of incident high-grade serous carcinomas (HGSC), specifically ovarian, primary peritoneal, or fallopian tube cancers

    Will be assessed using a stratified log rank test, stratifying for age. The effects of other covariates, such as familial history of gynecologic cancer, time to crossover for bilateral salpingectomy (BLS) patients, and age at study entry, will be adjusted for in Cox proportional hazard models. Patients who crossover will be analyzed according to the initial surgery received at study enrollment as this will reflect actual practice.

    Time frame: Up to 20 years

Secondary outcomes

  1. Health-related quality of life (QOL)

    Will be measured by the Functional Assessment of Cancer Therapy - Endocrine Symptom (FACT-ES). The FACT total score (calculated from the physical, functional, social and emotional well-being subscales) and ES subscale will be assessed. Scores range from 0 to 76. Higher scores indicate better QOL for the FACT-ES and better functioning for the Female Sexual Function Index (FSFI) total score.

    Time frame: Up to 24 months post-surgery

  2. Cancer distress

    Will be measured by the Impact of Events Scale (IES). The total score can range from 0 to 88, with higher scores indicating a greater impact of the event.

    Time frame: Up to 24 months post-surgery

  3. Medical decision making

    Will be measured by the Shared Decision Making Questionnaire (SDM-Q-9) and, Decisional Regret Scale. The SDM-Q-9 total score and Decisional Regret Scale total score at each time point of collection will be compared between arms using a t-test with a significance level of 0.05. A linear model will be used to assess the association of the SDM-Q-9 total score with treatment arm and patient characteristics such as age and race. A similar model will be used to assess the association of the Decisional Regret Scale total score with treatment arm and patient characteristics such as age, race, crossover from BLS arm, and hysterectomy status. Minimum score of 0 and a maximum score of 45. A higher score indicates a greater level of perceived shared decision-making in a consultation.

    Time frame: Up to 24 months post-surgery

  4. Incidence of adverse events

    Will be graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Counts and frequencies will be provided for the worst grade adverse event (AE) experienced by the patient by treatment arm. The distribution of AE grade in the BLS arm will be compared to the bilateral salpingo-oophorectomy arm using a chi-square test, or Fisher's exact test if cell frequencies are \< 5, at the one-sided 0.05 significance level.

    Time frame: Up to 20 years

  5. Estrogen deprivation symptoms (pre-menopaused patients only)

    Will be measured by the FACT-ES. The FACT total score (calculated from the physical, functional, social and emotional well-being subscales) and ES subscale will be assessed. Scores range from 0 to 76. Higher scores indicate better QOL for the FACT-ES and better functioning for the FSFI total score. Models will also include hormonal therapy as a covariate.

    Time frame: Up to 24 months post-surgery

  6. Sexual dysfunction (pre-menopausal patients only)

    Will be measured by the FSFI. Scores range from 0 to 36. Higher scores indicate better functioning for the FSFI total score.

    Time frame: Up to 24 months post-surgery

  7. Menopausal symptoms (pre-menopausal patients only)

    Will be measured by the Menopausal Symptom Checklist (MSCL). Models will also include hormonal therapy as a covariate. The MSCL total score and individual items will be compared between groups using the t-test and Wilcoxon test, respectively. The change from baseline in total score will be compared between groups at each follow-up time point. The change form baseline in the 3 items not included in the subscale scores will be compared between groups using the Wilcoxon test at each follow-up time point.

    Time frame: Up to 24 months post-surgery

Other outcomes

  1. Cost effectiveness

    Will be measured by European Quality of Life Five Dimension Five Level Scale Questionnaire. A Markov model will be used to model cost. Scores range from 0 to 100 with higher score indicating better overall health.

    Time frame: Up to 24 months post-surgery

  2. Sexual dysfunction (pre-menopausal patients only)

    Will be measured by selected Patient-Reported Outcomes Measurement Information System (PROMIS) screener and external sexual function items. Each item will be analyzed separately and compared between treatment arms using a chi-square test. Scores range from 0 to 100 with higher score indicating more of the concept being measured.

    Time frame: Up to 24 months-post surgery

  3. Health related (HR)-QOL

    Will examine the correlation between HR-QOL, as measured by the FACT, with menopausal symptoms, as measured by the MSCL, sexual dysfunction, as measured by FSFI, and PROMIS screener and external sexual function items and cancer distress as measured by the IES. Pearson correlation coefficients will be used for correlating the FACT total score with the FSFI overall score and Impact of Events Scale total distress score. Spearman correlation coefficients will be used to assess the correlation between FACT total score and the Menopausal Symptom Checklist symptoms, FSFI, and PROMIS items.

    Time frame: Up to 24 months post-surgery

  4. Risk-reducing medical decision making validation and assessment

    Measured by population-specific items examining the factors associated with the risk reducing surgical treatment choice. Will by assessed using the Risk-Reducing Medical Decision Making survey.

    Time frame: Up to 24 months post-surgery

07

Study locations

548 of 630 sites recruiting

Showing the first 100 of 630 sites across 3 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Pennington KP, Pugh SL, Huh W, Walker JL, Jewell E, Havrilesky LJ, Carter J, Muller CY, Drapkin R, Lankes HA, Castellano T, Zamorano AS, Blank SV, Kachnic LA. Optimization of Timing for Risk-Reducing Salpingectomy and Oophorectomy. Obstet Gynecol. 2025 Jan 1;145(1):21-30. doi: 10.1097/AOG.0000000000005781. Epub 2024 Nov 7. PubMed 39509704 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2020 (actual). Primary completion is estimated for Jun 2047, 321 months after the start.

Of 284 non-industry interventional studies with no phase under Ovarian Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 76. This study's planned 321 months is above that.

Counting every sponsor, half of 295 studies reached it within 46 months; a quarter within 23 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2020
First posted
Jan 31, 2020
StartActual
Sep 1, 2020
Primary completionEst.
Jun 30, 2047
CompletionEst.
Jun 30, 2047
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
57 sites added, 1 site removed. 14 sites changed recruiting status (10 now recruiting, 4 now suspended)
Show 14 sites
  • Augusta University Medical Center · Augusta, United StatesSuspended→Recruiting
  • Walter Reed National Military Medical Center · Bethesda, United StatesSuspended→Recruiting
  • Wayne State University/Karmanos Cancer Institute · Detroit, United StatesSuspended→Recruiting
  • Weisberg Cancer Treatment Center · Farmington Hills, United StatesSuspended→Recruiting
  • McLaren Cancer Institute-Flint · Flint, United StatesSuspended→Recruiting
  • Trinity Health Muskegon Hospital · Muskegon, United StatesSuspended→Recruiting
  • Mission Hospital · Asheville, United StatesRecruiting→Suspended
  • Hope Women's Cancer Centers-Asheville · Asheville, United StatesRecruiting→Suspended
  • Mercy Hospital Oklahoma City · Oklahoma City, United StatesRecruiting→Suspended
  • Bay Area Hospital · Coos Bay, United StatesRecruiting→Suspended
  • University of Texas Health Science Center at San Antonio · San Antonio, United StatesSuspended→Recruiting
  • CHUM - Centre Hospitalier de l'Universite de Montreal · Montreal, CanadaSuspended→Recruiting
  • Keimyung University-Dongsan Medical Center · Dalseo-gu, South KoreaSuspended→Recruiting
  • Yonsei University Health System-Severance Hospital · Seoul, South KoreaSuspended→Recruiting
Show 57 added (57 United States)
  • Holy Cross Hospital · Fort Lauderdale, United States
  • Saint Alphonsus Cancer Care Center-Boise · Boise, United States
  • Saint Alphonsus Cancer Care Center-Caldwell · Caldwell, United States
  • Saint Alphonsus Cancer Care Center-Nampa · Nampa, United States
  • John H Stroger Jr Hospital of Cook County · Chicago, United States
  • MyMichigan Medical Center Gratiot · Alma, United States
  • MyMichigan Medical Center Alpena · Alpena, United States
  • Hematology Oncology Consultants-Clarkston · Clarkston, United States
  • Trinity Health IHA Medical Group - Primary Care - Clarkston · Clarkston, United States
  • Henry Ford Health Saint John Hospital · Detroit, United States
  • Henry Ford River District Hospital · East China Township, United States
  • Cancer Hematology Centers - Flint · Flint, United States
  • Genesee Hematology Oncology PC · Flint, United States
  • Genesys Hurley Cancer Institute · Flint, United States
  • Hurley Medical Center · Flint, United States
  • MyMichigan Medical Center Gladwin · Gladwin, United States
  • Trinity Health Grand Rapids Hospital · Grand Rapids, United States
  • Henry Ford Saint John Hospital - Academic · Grosse Pointe Woods, United States
  • Henry Ford Saint John Hospital - Breast · Grosse Pointe Woods, United States
  • Henry Ford Saint John Hospital - Van Elslander · Grosse Pointe Woods, United States
  • University of Michigan Health - Sparrow Lansing · Lansing, United States
  • Henry Ford Saint John Hospital - Macomb Medical · Macomb, United States
  • Henry Ford Warren Hospital - Breast Macomb · Macomb, United States
  • MyMichigan Medical Center Midland · Midland, United States
  • MyMichigan Medical Center Mount Pleasant · Mount Pleasant, United States
  • Cancer and Hematology Centers of Western Michigan - Norton Shores · Norton Shores, United States
  • Michigan Healthcare Professionals Pontiac · Pontiac, United States
  • Trinity Health IHA Medical Group-Alice Gustafson Center · Pontiac, United States
  • Trinity Health Saint Joseph Mercy Oakland Hospital · Pontiac, United States
  • MyMichigan Medical Center Saginaw · Saginaw, United States
  • …and 27 more on the registry record
Show 1 removed
  • West Virginia University Charleston Division · Charleston, United States
Nov 6, 2026
Site contacts
Changed at 45 sites. See the sites
Show 45 sites
  • Mercy Cancer Center - Carmichael · Carmichael, United StatesContact person changed (no phone or email listed)
  • Mercy San Juan Medical Center · Carmichael, United StatesContact person changed (no phone or email listed)
  • Mercy Cancer Center - Elk Grove · Elk Grove, United StatesContact person changed (no phone or email listed)
  • Mercy Cancer Center - Rocklin · Rocklin, United StatesContact person changed (no phone or email listed)
  • Mercy Cancer Center - Sacramento · Sacramento, United StatesContact person changed (no phone or email listed)
  • Woodland Memorial Hospital · Woodland, United StatesContact person changed (no phone or email listed)
  • Florida Cancer Specialists - Bradenton Cancer Center · Bradenton, United StatesContact person changed (no phone or email listed)
  • Florida Cancer Specialists-Englewood · Englewood, United StatesContact person changed (no phone or email listed)
  • Sarasota Memorial Hospital-Venice · Nokomis, United StatesContact person changed (no phone or email listed)
  • Florida Cancer Specialists - Sarasota · Sarasota, United StatesContact person changed (no phone or email listed)
  • Intercoastal Medical Group - Cattleridge II · Sarasota, United StatesContact person changed (no phone or email listed)
  • First Physicians Group - Gastroenterology Obesity Medicine · Sarasota, United StatesContact person changed (no phone or email listed)
  • First Physicians Group - Silverstein Institute at Floyd Street · Sarasota, United StatesContact person changed (no phone or email listed)
  • First Physicians Group - Urology Robotic and Minimally Invasive Surgery · Sarasota, United StatesContact person changed (no phone or email listed)
  • Florida Cancer Specialists - Sarasota Downtown · Sarasota, United StatesContact person changed (no phone or email listed)
  • FPG - Surgical Oncology Clinics Gastrointestinal Oncology Surgery · Sarasota, United StatesContact person changed (no phone or email listed)
  • FPG - Surgical Oncology Clinics Gynecologic Oncology Surgery · Sarasota, United StatesContact person changed (no phone or email listed)
  • Sarasota Memorial Hospital · Sarasota, United StatesContact person changed (no phone or email listed)
  • Sarasota Memorial Health Care Center at University Parkway · Sarasota, United StatesContact person changed (no phone or email listed)
  • Florida Cancer Specialists - Venice Pinebrook · Venice, United StatesContact person changed (no phone or email listed)
  • Florida Cancer Specialists - Venice Island · Venice, United StatesContact person changed (no phone or email listed)
  • Augusta University Medical Center · Augusta, United StatesContact added g•••@augusta.edu · •••2388Contact added (no phone or email listed)
  • Norton Hospital Pavilion and Medical Campus · Louisville, United StatesContact person changed (no phone or email listed)
  • Norton Suburban Hospital and Medical Campus · Louisville, United StatesContact person changed (no phone or email listed)
  • Norton Audubon Hospital and Medical Campus · Louisville, United StatesContact person changed (no phone or email listed)
  • Norton Brownsboro Hospital and Medical Campus · Louisville, United StatesContact person changed (no phone or email listed)
  • Walter Reed National Military Medical Center · Bethesda, United StatesContact added •••2100Contact added (no phone or email listed)
  • Wayne State University/Karmanos Cancer Institute · Detroit, United StatesContact added c•••@karmanos.org · •••6266Contact added (no phone or email listed)
  • Weisberg Cancer Treatment Center · Farmington Hills, United StatesContact added c•••@karmanos.org · •••9790Contact added (no phone or email listed)
  • McLaren Cancer Institute-Flint · Flint, United StatesContact added c•••@karmanos.org · •••9790Contact added (no phone or email listed)
  • …and 15 more sites
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    57 sites added, 1 site removed. 14 sites changed recruiting status (10 now recruiting, 4 now suspended)
    Show 14 sites
    • Augusta University Medical Center · Augusta, United StatesSuspended→Recruiting
    • Walter Reed National Military Medical Center · Bethesda, United StatesSuspended→Recruiting
    • Wayne State University/Karmanos Cancer Institute · Detroit, United StatesSuspended→Recruiting
    • Weisberg Cancer Treatment Center · Farmington Hills, United StatesSuspended→Recruiting
    • McLaren Cancer Institute-Flint · Flint, United StatesSuspended→Recruiting
    • Trinity Health Muskegon Hospital · Muskegon, United StatesSuspended→Recruiting
    • Mission Hospital · Asheville, United StatesRecruiting→Suspended
    • Hope Women's Cancer Centers-Asheville · Asheville, United StatesRecruiting→Suspended
    • Mercy Hospital Oklahoma City · Oklahoma City, United StatesRecruiting→Suspended
    • Bay Area Hospital · Coos Bay, United StatesRecruiting→Suspended
    • University of Texas Health Science Center at San Antonio · San Antonio, United StatesSuspended→Recruiting
    • CHUM - Centre Hospitalier de l'Universite de Montreal · Montreal, CanadaSuspended→Recruiting
    • Keimyung University-Dongsan Medical Center · Dalseo-gu, South KoreaSuspended→Recruiting
    • Yonsei University Health System-Severance Hospital · Seoul, South KoreaSuspended→Recruiting
    Show 57 added (57 United States)
    • Holy Cross Hospital · Fort Lauderdale, United States
    • Saint Alphonsus Cancer Care Center-Boise · Boise, United States
    • Saint Alphonsus Cancer Care Center-Caldwell · Caldwell, United States
    • Saint Alphonsus Cancer Care Center-Nampa · Nampa, United States
    • John H Stroger Jr Hospital of Cook County · Chicago, United States
    • MyMichigan Medical Center Gratiot · Alma, United States
    • MyMichigan Medical Center Alpena · Alpena, United States
    • Hematology Oncology Consultants-Clarkston · Clarkston, United States
    • Trinity Health IHA Medical Group - Primary Care - Clarkston · Clarkston, United States
    • Henry Ford Health Saint John Hospital · Detroit, United States
    • Henry Ford River District Hospital · East China Township, United States
    • Cancer Hematology Centers - Flint · Flint, United States
    • Genesee Hematology Oncology PC · Flint, United States
    • Genesys Hurley Cancer Institute · Flint, United States
    • Hurley Medical Center · Flint, United States
    • MyMichigan Medical Center Gladwin · Gladwin, United States
    • Trinity Health Grand Rapids Hospital · Grand Rapids, United States
    • Henry Ford Saint John Hospital - Academic · Grosse Pointe Woods, United States
    • Henry Ford Saint John Hospital - Breast · Grosse Pointe Woods, United States
    • Henry Ford Saint John Hospital - Van Elslander · Grosse Pointe Woods, United States
    • University of Michigan Health - Sparrow Lansing · Lansing, United States
    • Henry Ford Saint John Hospital - Macomb Medical · Macomb, United States
    • Henry Ford Warren Hospital - Breast Macomb · Macomb, United States
    • MyMichigan Medical Center Midland · Midland, United States
    • MyMichigan Medical Center Mount Pleasant · Mount Pleasant, United States
    • Cancer and Hematology Centers of Western Michigan - Norton Shores · Norton Shores, United States
    • Michigan Healthcare Professionals Pontiac · Pontiac, United States
    • Trinity Health IHA Medical Group-Alice Gustafson Center · Pontiac, United States
    • Trinity Health Saint Joseph Mercy Oakland Hospital · Pontiac, United States
    • MyMichigan Medical Center Saginaw · Saginaw, United States
    • …and 27 more on the registry record
    Show 1 removed
    • West Virginia University Charleston Division · Charleston, United States
    Site contacts Changed at 45 sites. See the sites
    Show 45 sites
    • Mercy Cancer Center - Carmichael · Carmichael, United StatesContact person changed (no phone or email listed)
    • Mercy San Juan Medical Center · Carmichael, United StatesContact person changed (no phone or email listed)
    • Mercy Cancer Center - Elk Grove · Elk Grove, United StatesContact person changed (no phone or email listed)
    • Mercy Cancer Center - Rocklin · Rocklin, United StatesContact person changed (no phone or email listed)
    • Mercy Cancer Center - Sacramento · Sacramento, United StatesContact person changed (no phone or email listed)
    • Woodland Memorial Hospital · Woodland, United StatesContact person changed (no phone or email listed)
    • Florida Cancer Specialists - Bradenton Cancer Center · Bradenton, United StatesContact person changed (no phone or email listed)
    • Florida Cancer Specialists-Englewood · Englewood, United StatesContact person changed (no phone or email listed)
    • Sarasota Memorial Hospital-Venice · Nokomis, United StatesContact person changed (no phone or email listed)
    • Florida Cancer Specialists - Sarasota · Sarasota, United StatesContact person changed (no phone or email listed)
    • Intercoastal Medical Group - Cattleridge II · Sarasota, United StatesContact person changed (no phone or email listed)
    • First Physicians Group - Gastroenterology Obesity Medicine · Sarasota, United StatesContact person changed (no phone or email listed)
    • First Physicians Group - Silverstein Institute at Floyd Street · Sarasota, United StatesContact person changed (no phone or email listed)
    • First Physicians Group - Urology Robotic and Minimally Invasive Surgery · Sarasota, United StatesContact person changed (no phone or email listed)
    • Florida Cancer Specialists - Sarasota Downtown · Sarasota, United StatesContact person changed (no phone or email listed)
    • FPG - Surgical Oncology Clinics Gastrointestinal Oncology Surgery · Sarasota, United StatesContact person changed (no phone or email listed)
    • FPG - Surgical Oncology Clinics Gynecologic Oncology Surgery · Sarasota, United StatesContact person changed (no phone or email listed)
    • Sarasota Memorial Hospital · Sarasota, United StatesContact person changed (no phone or email listed)
    • Sarasota Memorial Health Care Center at University Parkway · Sarasota, United StatesContact person changed (no phone or email listed)
    • Florida Cancer Specialists - Venice Pinebrook · Venice, United StatesContact person changed (no phone or email listed)
    • Florida Cancer Specialists - Venice Island · Venice, United StatesContact person changed (no phone or email listed)
    • Augusta University Medical Center · Augusta, United StatesContact added g•••@augusta.edu · •••2388Contact added (no phone or email listed)
    • Norton Hospital Pavilion and Medical Campus · Louisville, United StatesContact person changed (no phone or email listed)
    • Norton Suburban Hospital and Medical Campus · Louisville, United StatesContact person changed (no phone or email listed)
    • Norton Audubon Hospital and Medical Campus · Louisville, United StatesContact person changed (no phone or email listed)
    • Norton Brownsboro Hospital and Medical Campus · Louisville, United StatesContact person changed (no phone or email listed)
    • Walter Reed National Military Medical Center · Bethesda, United StatesContact added •••2100Contact added (no phone or email listed)
    • Wayne State University/Karmanos Cancer Institute · Detroit, United StatesContact added c•••@karmanos.org · •••6266Contact added (no phone or email listed)
    • Weisberg Cancer Treatment Center · Farmington Hills, United StatesContact added c•••@karmanos.org · •••9790Contact added (no phone or email listed)
    • McLaren Cancer Institute-Flint · Flint, United StatesContact added c•••@karmanos.org · •••9790Contact added (no phone or email listed)
    • …and 15 more sites
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04251052
Lead sponsor
NRG Oncology
Responsible party
Sponsor
First posted
Jan 31, 2020
Start date
Sep 1, 2020
Primary completion
Jun 30, 2047 (estimated)
Completion
Jun 30, 2047 (estimated)
Last update
Nov 6, 2026

Study contacts

Kathryn P Pennington
principal investigator · NRG Oncology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion